2026-07-13
notable
Not Yet Recruiting→Recruiting Study Status, Sponsor/Collaborators, Study Description, Study Design, Arms and Interventions, Eligibility, Contacts/Locations v1
Trial statusNot Yet Recruiting→Recruiting
Primary completion date2027-07→2027-03
Start dateestimated 2024-06→confirmed 2024-08-05
Enrollment target131→113
Study arms2→3
InterventionsAdebrelimab (Drug), SHR-A1811 (Drug), SHR-A1921 (Drug)→Adebrelimab (Drug), SHR-A1811 (Drug), SHR-A1921 (Drug), SHR-A2102 (Drug)
Eligibility criteria+189 characters
Inclusion Criteria:
18 years to 75 years old (including boundary values), female patients with breast cancer;
ECOG PS Score: 0~1;
Histologically or cytologically confir [...] ive advanced breast cancer;
Disease progression after prior ≥1-2 linesline of systemic therapy; if HR-positive, prior CDK4/6 inhibitor [...] symptoms, or treated, stable brain metastases are eligible;
No prior PD-(L)1 inhibitor;
Patients must have a life expectancy ≥ 6 months;
Adequate or [...] (no corrective treatment within 14 days before first dose);
PatientsWomen of childbearing potential should have a negative urine or s [...] months after the [...]
Study sitesdetails revised at 1 of 1 site